哮喘遗传学与基因组学引导的药物靶点发现
近3年大规模遗传研究使独立哮喘相关遗传位点增至128个,文章将遗传变异与潜在药物靶点关联,提出基因组学引导的靶点发现可推动现有药物重定位和新药开发。
要点
- 近3年大规模遗传研究将独立哮喘相关遗传位点增至128个。
- 基因组学引导的靶点发现有望推动药物重定位与新药开发。
核心结论
- 哮喘遗传学研究已识别128个独立相关位点,基因组学引导的靶点发现可促进现有药物重定位和新药开发。
- 需进一步研究明确哮喘相关基因变异在患者亚组中的功能意义及其参与的生物网络。
研究设计与样本
- 本文为系列文章(Series paper),综述过去13年哮喘遗传学进展,未报告原始研究样本量。
主要发现
- 过去3年大规模遗传研究将独立哮喘相关遗传位点增至128个。
- 文章将哮喘遗传变异与可能的药物靶点关联。
临床怎么用
- 基因组学引导的靶点发现可用于筛选哮喘现有药物重定位的候选靶点。
- 遗传变异与靶点的关联可为开发针对哮喘潜在机制的新药提供线索。
局限性
- 哮喘相关基因变异在患者亚组中的功能意义尚待建立。
- 相关基因变异所参与的生物学网络尚待描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.
引用
- El-Husseini ZW, Gosens R, Dekker F, et al. The genetics of asthma and the promise of genomics-guided drug target discovery. Lancet Respir Med. 2020. PMID: 32910899. doi:10.1016/S2213-2600(20)30363-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。